Peter Noymer, PhD, is co-founder and CEO of 153 Therapeutics, a UCSF spinout developing novel, small-molecule therapeutics for Parkinson’s Disease and other CNS disorders. Peter also serves as Executive Chairman of PyrAmes Inc., a Stanford University digital health spinout. Prior to co-founding 153 Therapeutics, he served as an EIR with UCSF Innovation Ventures, helping to establish key proof-of-concept milestones that led to company formation. From 2017 to 2019, Peter was CEO of Kedalion Therapeutics, a clinical-stage ophthalmology therapeutics company (acquired by Novartis). From 2013 to 2017, Peter was CTO and then COO at SteadyMed Therapeutics (acquired by United Therapeutics). Earlier, he served as VP of Product R&D at Alexza Pharmaceuticals (acquired by Grupo Ferrer), as well as in management roles at Aradigm Corporation. Peter received MS and PhD degrees from MIT, and a BS degree from Princeton University.